CoChat
Sign Up
Cited by 333Cholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, Martin, Anand, Ravi, Messina Jr, John, Hartman, Richard, Veach, Jeffrey·2000·European Neurology
DOI 10.1159/000008243
Open this paper in CoChat — free account

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

Overview

Integrity signals

Registry

Crossref · 10.1159/000008243

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 333

Related

See all

Metadata

Authors
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J.
Affiliations
Indiana University Indianapolis (US)
ORCID
Venue
European Neurology
Publisher
S. Karger AG
Published
2000
Volume
44
Issue
4
Pages
236-241
ISSN
  • 0014-3022 (ISSN-L)
  • 1421-9913
DOI
10.1159/000008243
OpenAlex
W2076676029
Cited by
332
References
10
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 9 · 2012: 7
FWCI
15.52
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
rivastigmine, Alzheimer's disease, cholinesterase inhibitors, cognitive function, open-label extension, long-term efficacy
MeSH terms
Rivastigmine, Age Factors, Aged, Alzheimer Disease, Carbamates, Cholinesterase Inhibitors, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Time Factors, Treatment Outcome, Disease Progression, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review